A phase 2 study of ipatasertib in combination with pembrolizumab for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck

被引：0
|
作者：
Thomas, Jacob S.
Hsu, Robert
Villaflor, Victoria
Riess, Jonathan
Nieva, Jorge
Krailo, Mark
Gutkind, Silvio
Colevas, Dimitri
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT047
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.
    Fayette, Jerome
    Clatot, Florian
    Brana, Irene
    Saada, Esma
    van Herpen, Carla M. L. -
    Mazard, Thibault
    Perez, Cesar Augusto
    Tabernero, Josep
    Le Tourneau, Christophe
    Hollebecque, Antoine
    Arrula, Virginia Arrazubi
    Fontana, Elisa
    Kato, Shumei
    Sacco, Assuntina G.
    Harandi, Amir
    De Boer, J. P.
    Hellyer, Jessica
    Pennella, Eduardo
    Joe, Andrew K.
    Daste, Amaury
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prospective phase I/II study
    Fuereder, Thorsten
    Minichsdorfer, Christoph
    Mittlboeck, Martina
    Wagner, Christina
    Heller, Gerwin
    Putz, Eva M.
    Oberndorfer, Felicitas
    Mullauer, Leonhard
    Aretin, Marie-Bernadette
    Czerny, Christian
    Schwarz-Nemec, Ursula
    ORAL ONCOLOGY, 2022, 124
  • [43] Pembrolizumab plus docetaxel for the treatment of recurrent metastatic head and neck cancer: A prospective phase I/II study
    Fuereder, T.
    Minichsdorfer, C.
    Mittlboeck, M.
    Wagner, C.
    Oberndorfer, F.
    Mullauer, L.
    Aretin, M-B.
    Czerny, C.
    Schwarz-Nemec, U.
    ANNALS OF ONCOLOGY, 2020, 31 : S665 - S665
  • [44] A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Bossi, P.
    Miceli, R.
    Locati, L. D.
    Ferrari, D.
    Vecchio, S.
    Moretti, G.
    Denaro, N.
    Caponigro, F.
    Airoldi, M.
    Moro, C.
    Vaccher, E.
    Sponghini, A.
    Caldara, A.
    Rinaldi, G.
    Ferrau, F.
    Nole, F.
    Lo Vullo, S.
    Tettamanzi, F.
    Hollander, L.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2820 - 2826
  • [45] First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study
    Harrington, Kevin
    Siu, Lillian L.
    Burtness, Barbara
    Cohen, Ezra
    Licitra, Lisa
    Rischin, Danny
    Zhu, Ying
    Okpara, Chinyere E.
    Pinheiro, Cecilia
    Swaby, Ramona F.
    Machiels, Jean-Pascal
    Tahara, Makoto
    ORAL ONCOLOGY, 2021, 118
  • [46] Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Siu, Lillian L.
    Burtness, Barbara
    Cohen, Ezra E. W.
    Harrington, Kevin Joseph
    Licitra, Lisa F.
    Rischin, Danny
    Zhu, Ying
    Lee, Chooi Peng
    Pinheiro, Cecilia
    Swaby, Ramona F.
    Machiels, Jean-Pascal H.
    Tahara, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck
    Vermorken, J. B.
    Licitra, L.
    Stoehlmacher-Williams, J.
    Dietz, A.
    Lopez-Picazo, J. M.
    Hamid, O.
    Hossain, A. M.
    Chang, S. -C.
    Gauler, T. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (13) : 2877 - 2883
  • [48] Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer
    Chen, Tien-Hua
    Chang, Peter Mu-Hsin
    Yang, Muh-Hwa
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2021, 84 (04) : 361 - 367
  • [49] Real-world use of first-line pembrolizumab plus platinum plus taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma
    Black, Christopher M.
    Zheng, Dandan
    Hair, Gleicy M.
    Ai, Lei
    Wang, Liya
    Goto, Daisuke
    Lerman, Nati
    Bidadi, Behzad
    Hanna, Glenn J.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [50] Pembrolizumab for cisplatin-failure recurrent/metastatic head and neck squamous cell carcinoma
    Chen, W-C.
    Chang, P. M-H.
    Lee, Y-T.
    Lu, W-B.
    Yang, M-H.
    ANNALS OF ONCOLOGY, 2016, 27
12345